Masitinib plus standard care for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests whether adding the drug masitinib to standard ALS care (riluzole) slows the disease more than standard care alone. It may help people with ALS who are in a certain stage of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with ALS (probable or definite).
- You have been taking riluzole for at least 30 days.
- Your first ALS symptoms started no more than 36 months ago.
- Your disease progression rate is within a certain range (based on a standard ALS scale).
- Your breathing function (FVC) is at least 70% of the expected value.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
This Phase 3 study tests whether masitinib works better than an inactive pill (placebo) to slow ALS progression and keep it safe. It is meant for people recently diagnosed with ALS who meet specific breathing and function score requirements.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial tests two new medicines (galunisertib and nerandomilast) together in people with a specific type of ALS. The combination may slow down the damage in the nervous system, and the trial is looking at whether it's safe and helps.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.